Literature DB >> 24717020

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports.

Mehran Karimi, Nader Cohan, Parisa Pishdad.   

Abstract

OBJECTIVE AND IMPORTANCE: Extramedullary hematopoiesis (EMH) is evidenced by erythropoietic masses, which occurs as a compensatory mechanism to overcome hypoxia during chronic anemia. EMH masses in spinal cord could lead to cord compression and neurological symptoms. Besides transfusion, radiotherapy, and surgery, hydroxyurea (HU) is also a treatment strategy in EMH. CLINICAL
PRESENTATION: We described four cases of beta thalassemia with EMH who were treated with HU as a monotherapy. INTERVENTION (AND TECHNIQUE): HU therapy was done in all patients without any transfusion during therapy.
CONCLUSION: HU is a good treatment option for patients with EMH and it could be a substitute for radiotherapy and invasive surgery or regular blood transfusion.

Entities:  

Keywords:  Chronic anemia; Extramedullary hematopoiesis; Hydroxyurea; Thalassemia

Mesh:

Substances:

Year:  2014        PMID: 24717020     DOI: 10.1179/1607845414Y.0000000168

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  10 in total

1.  Impact of hydroxyurea therapy on serum fatty acids of β-thalassemia patients.

Authors:  Ayesha Iqbal; Amna Jabbar Siddiqui; Jian-Hua Huang; Saqib Hussain Ansari; Syed Ghulam Musharraf
Journal:  Metabolomics       Date:  2018-01-31       Impact factor: 4.290

2.  Intracranial Hematopoiesis in Beta Thalassemia: A Case Series.

Authors:  Rashid Merchant; Amitkumar J Choudhari; Mitusha Verma; Deepak P Patkar; Pezad Doctor
Journal:  Indian J Pediatr       Date:  2018-01-25       Impact factor: 1.967

Review 3.  A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.

Authors:  Nirmani Yasara; Anuja Premawardhena; Sachith Mettananda
Journal:  Orphanet J Rare Dis       Date:  2021-03-01       Impact factor: 4.123

4.  Comparative study of radiographic and laboratory findings between Beta thalassemia major and Beta thalassemia intermedia patients with and without treatment by hydroxyurea.

Authors:  Amin Abolhasani Foroughi; Hosein Ghaffari; Sezaneh Haghpanah; Masoume Nazeri; Roghieh Ghaffari; Marzieh Bardestani; Mehran Karimi
Journal:  Iran Red Crescent Med J       Date:  2015-02-01       Impact factor: 0.611

5.  Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy Pattern.

Authors:  Ayesha Iqbal; Saqib Hussain Ansari; Sadia Parveen; Ishtiaq Ahmad Khan; Amna Jabbar Siddiqui; Syed Ghulam Musharraf
Journal:  Sci Rep       Date:  2018-10-11       Impact factor: 4.379

6.  A large intrathoracic extramedullary hematopoiesis in alpha-thalassemia: A case report.

Authors:  Jianan Chen; Yuan-Ling Liu; Min-Zhen Lu; Xing-Lin Gao
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

7.  Adrenal extramedullary hematopoiesis in the setting of anti-Diego antibody and congenital dyserythropoietic anemia.

Authors:  Janet Rae Julson; Lee Michelle Hilliard; Elizabeth Mroczek-Musulman; Elizabeth A Beierle
Journal:  J Pediatr Surg Case Rep       Date:  2022-03-07

8.  Thalassemia, extramedullary hematopoiesis, and spinal cord compression: A case report.

Authors:  Syed Sarmad Bukhari; Muhammad Junaid; Mamoon Ur Rashid
Journal:  Surg Neurol Int       Date:  2016-03-02

9.  Spinal cord compression due to extramedullary hematopoiesis in a patient with E-beta-thalassemia managed without radiation or surgery.

Authors:  Van T La; Michael Diatte; Johnathan Gaston; Dallas Dick; Raed Sweiss; Zahra Pakbaz
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-08-23

10.  A Case of Multifocal Extramedullary and Non-Hepatosplenic Extramedullary Hematopoiesis in a 43-Year-Old Man with a History of Congenital Eisenmenger Syndrome.

Authors:  Krzysztof Gawroński; Kamila Kruczkowska-Tarantowicz; Piotr Rzepecki; Daniel Lisicki
Journal:  Am J Case Rep       Date:  2022-03-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.